91 results on '"Vigneault, Eric"'
Search Results
2. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
3. 172 The Impact of Androgen-Deprivation Therapy on Ceramides, a Potential Biomarker of Outcomes of Prostate Cancer for Patients Treated with EBRT and HDR Brachytherapy Boost
4. 33 Efficacy of Ultra Hypofrationed Radiotherapy Combined with HDR Brachytherapy
5. Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study
6. GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina
7. PSOR3 Presentation Time: 11:40 AM
8. PP12 Presentation Time: 11:20 AM
9. 154: The Role of CAPRA Score as a Predictor of Outcomes in High-Risk Prostate Cancer Patients Treated with EBRT Plus HDR Brachytherapy Boost
10. 109: Prostate Cancer-Specific Death Rates in Localized Prostate Cancer: Data from Two Randomized Trials
11. 101: Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study
12. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526)
13. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126
14. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial
15. Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technology
16. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study
17. 34: Infectious Risk After Prostatic Transrectal Fiducial Marker Implantation in Radiation Therapy
18. 6: Ultra-Hypofractionated (UHF) Compared to Moderate-Hypofractionated (MHF) Prostate IGRT with HDR Brachytherapy Boost(BB): Four-Year Toxicities and Local Control
19. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate
20. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
21. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost
22. 163: Mapping The Current State of Canadian Oncology Interest Groups
23. 15: Acura Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
24. 10: NCI Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG 0526)
25. 14: Seventeen Years Experience of Ebrt Plus Hdr Brachytherapy Boost in High-Risk Localized Prostate Cancer Patients: A Competing Risks Analysis
26. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial
27. The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant
28. 55 The Advantages of TRUS When Compared to CT Planning for HDR Prostate Treatment
29. A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
30. 90 Ultra-Hypo (UHF) Compared to Moderate-Hypo (MHF) Fractionated Prostate IGRT with HDR Brachytherapy Boost: Long Term Toxicity, Acceptability and Efficiency of Delivery
31. 24 Subsequent Androgen Deprivation Therapy After Initial Treatment in Intermediate Risk Prostate Cancer: Prospective Data from a Phase III Trial
32. National Trends and Dynamic Responses in the Canadian Radiation Oncology Workforce From 1990 to 2018
33. MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes
34. Feasibility of Intraprostatic Prostate Cancer Imaging with FCH-PET/CT for Preoperative Planning of Image-Guided HDR Brachytherapy
35. The Impact of Dose to Bladder Neck on Urinary Toxicity in Patients Treated with HDR Brachytherapy Boost for Prostate Cancer
36. Long-Term Results of NRG Oncology/RTOG 0321 A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate
37. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526)
38. In Regard to Bossi et al
39. The Impact of Intraprostatic Calcifications on Biochemical Control after Permanent Prostate Implant
40. A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
41. Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
42. Real-time electromagnetic tracking–based treatment platform for high-dose-rate prostate brachytherapy: Clinical workflows and end-to-end validation
43. Can a Dominant Intraprostatic Lesion (DIL) Boost with Permanent I-125 Prostate Implants, Altered Outcomes and Improve Biochemical Disease-Free Survival (bDFS) in Intermediate Risk Prostate Cancer?
44. Multicenter Evaluation of Biochemical Relapse–Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System
45. High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes
46. Effect of Different Hypofractionated Regimens Combination on Clinical Outcomes in Prostate Cancer Patients Treated with High Dose-Rate Brachytherapy Boost
47. A Prospective Phase II Trial of Trans-Perineal Ultra-Sound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiotherapy (NRG/RTOG 0526)
48. The Practice of Radiation Oncology in Canada
49. Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy
50. Does prostate volume has an impact on biochemical failure in patients with localized prostate cancer treated with HDR boost?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.